| The clinical utility of C‐peptide measurement in the care of patients with diabetes AG Jones, AT Hattersley Diabetic medicine 30 (7), 803-817, 2013 | 719 | 2013 |
| Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data JM Dennis, BM Shields, WE Henley, AG Jones, AT Hattersley The Lancet Diabetes & Endocrinology 7 (6), 442-451, 2019 | 355 | 2019 |
| The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells RA Oram, AG Jones, REJ Besser, BA Knight, BM Shields, RJ Brown, ... Diabetologia 57, 187-191, 2014 | 332 | 2014 |
| A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults RA Oram, K Patel, A Hill, B Shields, TJ McDonald, A Jones, AT Hattersley, ... Diabetes care 39 (3), 337-344, 2016 | 326 | 2016 |
| Specific C-Terminal Cleavage and Inactivation of Interleukin-8 by Invasive Disease Isolates of Streptococcus pyogenes RJ Edwards, GW Taylor, M Ferguson, S Murray, N Rendell, A Wrigley, ... The Journal of infectious diseases 192 (5), 783-790, 2005 | 242 | 2005 |
| Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes AG Jones, TJ McDonald, BM Shields, AV Hill, CJ Hyde, BA Knight, ... Diabetes care 39 (2), 250-257, 2016 | 179 | 2016 |
| Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes NJ Thomas, AL Lynam, AV Hill, MN Weedon, BM Shields, RA Oram, ... Diabetologia 62 (7), 1167-1172, 2019 | 136 | 2019 |
| Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature BM Shields, JL Peters, C Cooper, J Lowe, BA Knight, RJ Powell, A Jones, ... BMJ open 5 (11), 2015 | 122 | 2015 |
| Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and … JM Dennis, WE Henley, MN Weedon, M Lonergan, LR Rodgers, ... Diabetes care 41 (9), 1844-1853, 2018 | 121 | 2018 |
| Logistic regression has similar performance to optimised machine learning algorithms in a clinical setting: application to the discrimination between type 1 and type 2 diabetes … AL Lynam, JM Dennis, KR Owen, RA Oram, AG Jones, BM Shields, ... Diagnostic and prognostic research 4, 1-10, 2020 | 104 | 2020 |
| Adult-Onset Type 1 Diabetes: Current Understanding and Challenges RD Leslie, C Evans-Molina, J Freund-Brown, R Buzzetti, D Dabelea, ... Diabetes Care 44 (11), 2449-2456, 2021 | 100 | 2021 |
| Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes REJ Besser, J Ludvigsson, AG Jones, TJ McDonald, BM Shields, ... Diabetes care 34 (3), 607-609, 2011 | 92 | 2011 |
| Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017 HJ Curtis, JM Dennis, BM Shields, AJ Walker, S Bacon, AT Hattersley, ... Diabetes, Obesity and Metabolism 20 (9), 2159-2168, 2018 | 90 | 2018 |
| Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis SV Hope, S Wienand-Barnett, M Shepherd, SM King, C Fox, K Khunti, ... British Journal of General Practice 66 (646), e315-e322, 2016 | 89 | 2016 |
| Understanding the manifestation of diabetes in sub Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review D Kibirige, W Lumu, AG Jones, L Smeeth, AT Hattersley, MJ Nyirenda Clinical diabetes and endocrinology 5 (1), 1-8, 2019 | 86 | 2019 |
| Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short-and long-term glycemic response to DPP-4 inhibitor therapy JM Dennis, BM Shields, AV Hill, BA Knight, TJ McDonald, LR Rodgers, ... Diabetes care 41 (4), 705-712, 2018 | 85 | 2018 |
| Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: a retrospective analysis of primary care data, 2010–2017 JM Dennis, WE Henley, AP McGovern, AJ Farmer, N Sattar, RR Holman, ... Diabetes, Obesity and Metabolism 21 (7), 1576-1584, 2019 | 77 | 2019 |
| Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes AG Jones, TJ McDonald, BM Shields, W Hagopian, AT Hattersley Diabetes Care 44 (6), 1243-1251, 2021 | 71 | 2021 |
| Sustained influence of metformin therapy on circulating glucagon‐like peptide‐1 levels in individuals with and without type 2 diabetes D Preiss, A Dawed, P Welsh, A Heggie, AG Jones, J Dekker, R Koivula, ... Diabetes, Obesity and Metabolism 19 (3), 356-363, 2017 | 69 | 2017 |
| Random non‐fasting C–peptide: bringing robust assessment of endogenous insulin secretion to the clinic SV Hope, BA Knight, BM Shields, AT Hattersley, TJ McDonald, AG Jones Diabetic Medicine 33 (11), 1554-1558, 2016 | 63 | 2016 |
